— Poster presented at the 30 th European Congress on Obesity (ECO 2023) shows addition of QSIVA provides benefits compared with Digital Lifestyle Intervention (DLI) alone in improving health outcomes in adults with obesity — AMSTERDAM, Netherlands, May 17, 2023 (GLOBE NEWSWIRE) -- VIVUS BV, the

CAMPBELL, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- VIVUS LLC today announced the promotion of Santosh T. Varghese, MD, to President VIVUS Global Pharmaceutical Development. With more than 25 years of U.S. and global pharmaceutical industry experience, including more than a decade at VIVUS, Dr.

CAMPBELL, Calif., July 20, 2022 (GLOBE NEWSWIRE) -- VIVUS LLC today announced that the U.S. Food and Drug Administration (FDA) approved QSYMIA (phentermine and topiramate extended-release capsules) CIV for use in the treatment of obesity in adolescents (12-17 years old) with an initial body-mass

CAMPBELL, Calif. , Dec. 11, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (the “ Company ”), a biopharmaceutical company, today announced that it has received approval from the United States Bankruptcy Court for the District of Delaware (the “ Bankruptcy Court ”) on its Second Amended   Joint Prepackaged

Virtual office visits and smart health devices available through the VIVUS Health Platform give physicians new tools for optimizing patient care and protecting the health of those at increased risk for COVID-19 CAMPBELL, Calif. , March 31, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc.

-Post-marketing study designed to evaluate Qsymia as an approach to weight management in a growing patient population with significant unmet medical need- CAMPBELL, Calif. , March 02, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced

- VIVUS to Receive Milestone Payment from Alvogen ; Significant Worldwide Growth Potential for Qsymia - CAMPBELL, Calif. , Feb. 19, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) (the “Company”), a biopharmaceutical company, announced today that its Korean marketing partner, Alvogen , has

CAMPBELL, Calif. , Feb. 05, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (“VIVUS”), a biopharmaceutical company, today announced that the U.S. Food and Drug Administration ( FDA ) has approved the supplemental New Drug Application (sNDA) for an improved formulation of PANCREAZE ®

CAMPBELL, Calif. , Dec. 31, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, today announced that on December 30, 2019 its board of directors adopted a new stockholder rights plan to replace the Company’s stockholder rights plan that expired in

-Data published in Diabetes, Obesity and Metabolism demonstrate that Qsymia provides statistically significant weight loss compared with placebo over an 8 week period, provide basis for ongoing 56 week phase 4 study in obese adolescents- CAMPBELL, Calif. , Dec.